Membrane-localized activation of glucuronide prodrugs by β-glucuronidase enzymes

Cancer Gene Therapy

Volumn 14, Issue 2, 2007, Pages 187-200

  Chen, K C ^a   Cheng, T L ^b   Leu, Y L ^c   Prijovich, Z M ^a   Chuang, C H ^b   Chen, B M ^a   Roffler, S R ^a  

^a INSTITUTE OF BIOMEDICAL SCIENCES   (Taiwan)

^b KAOHSIUNG MEDICAL UNIVERSITY   (Taiwan)

^c CHIA NAN UNIVERSITY OF PHARMACY AND SCIENCE   (Taiwan)

Author keywords

glucuronidase; Chimeric receptor; GDEPT; p hydroxy aniline mustard; Prodrug; Surface expression

Indexed keywords

4 HYDROXYANILINE MUSTARD GLUCURONIDE; 9 AMINOCAMPTOTHECIN GLUCURONIDE; B7 ANTIGEN; BETA GLUCURONIDASE; GLUCURONIDE; IMMUNOGLOBULIN; PRODRUG; UNCLASSIFIED DRUG;

ANIMAL CELL; ANTINEOPLASTIC ACTIVITY; ARTICLE; BYSTANDER EFFECT; CELL KILLING; CONTROLLED STUDY; DRUG ACTIVATION; DRUG EFFICACY; DRUG POTENCY; ENZYME ACTIVITY; ESCHERICHIA COLI; GENE DIRECTED ENZYME PRODRUG THERAPY; GENE EXPRESSION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MEMBRANE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DOMAIN; SUBCUTANEOUS TISSUE TUMOR; TUMOR CELL; TUMOR CELL DESTRUCTION;

3T3 CELLS; ANIMALS; BLOTTING, WESTERN; CELL LINE, TUMOR; DNA, COMPLEMENTARY; FLOW CYTOMETRY; GLUCURONIDASE; GLUCURONIDES; HUMANS; MICE; PRODRUGS; RECOMBINANT PROTEINS;

MURINAE;

EID: 33846245971     PISSN: 09291903     EISSN: 14765500     Source Type: Journal    
DOI: 10.1038/sj.cgt.7700999     Document Type: Article

References (54)

1. Hamstra DA, Lee KC, Tychewicz JM, Schepkin VD, Moffat BA, Chen M et al. The use of 19F spectroscopy and diffusion-weighted MRI to evaluate differences in gene-dependent enzyme prodrug therapies. Mol Ther 2004; 10: 916-928.
2. Moolten FL, Wells JM. Curability of tumors bearing herpes thymidine kinase genes transferred by retroviral vectors. J Natl Cancer Inst 1990; 82: 297-300.
3. Sung MW, Yeh HC, Thung SN, Schwartz ME, Mandeli JP, Chen SH et al. Intratumoral adenovirus-mediated suicide gene transfer for hepatic metastases from colorectal adenocarcinoma: results of a phase I clinical trial. Mol Ther 2001; 4: 182-191.
4. Pandha HS, Martin LA, Rigg A, Hurst HC, Stamp GW, Sikora K et al. Genetic prodrug activation therapy for breast cancer: A phase I clinical trial of erbB-2-directed suicide gene expression. J Clin Oncol 1999; 17: 2180-2189.
5. Mesnil M, Yamasaki H. Bystander effect in herpes simplex virus-thymidine kinase/ganciclovir cancer gene therapy: role of gap-junctional intercellular communication. Cancer Res 2000; 60: 3989-3999.
6. Rubsam LZ, Davidson BL, Shewach DS. Superior cytotoxicity with ganciclovir compared with acyclovir and 1-beta-D-arabinofuranosylthymine in herpes simplex virus-thymidine kinase-expressing cells: a novel paradigm for cell killing. Cancer Res 1998; 58: 3873-3882.
7. Nishida M, Futami S, Morita I, Maekawa K, Murota SI. Hypoxia- reoxygenation inhibits gap junctional communication in cultured human umbilical vein endothelial cells. Endothelium 2000; 7: 279-286.
8. Thust R, Tomicic M, Klocking R, Voutilainen N, Wutzler P, Kaina B. Comparison of the genotoxic and apoptosis-inducing properties of ganciclovir and penciclovir in Chinese hamster ovary cells transfected with the thymidine kinase gene of herpes simplex virus-1: implications for gene therapeutic approaches. Cancer Gene Ther 2000; 7: 107-117.
9. Huber BE, Austin EA, Richards CA, Davis ST, Good SS. Metabolism of 5-fluorocytosine to 5-fluorouracil in human colorectal tumor cells transduced with the cytosine deaminase gene: significant antitumor effects when only a small percentage of tumor cells express cytosine deaminase. Proc Natl Acad Sci USA 1994; 91: 8302-8306.
10. Lawrence TS, Rehemtulla A, Ng EY, Wilson M, Trosko JE, Stetson PL. Preferential cytotoxicity of cells transduced with cytosine deaminase compared to bystander cells after treatment with 5-flucytosine. Cancer Res 1998; 58: 2588-2593.
11. Haberkorn U, Oberdorfer F, Gebert J, Morr I, Haack K, Weber K et al. Monitoring gene therapy with cytosine deaminase: in vitro studies using tritiated-5-fluorocytosine. J Nucl Med 1996; 37: 87-94.
12. Miller CR, Williams CR, Buchsbaum DJ, Gillespie GY. Intratumoral 5-fluorouracil produced by cytosine deaminase/5-fluorocytosine gene therapy is effective for experimental human glioblastomas. Cancer Res 2002; 62: 773-780.
13. Shand N, Weber F, Mariani L, Bernstein M, Gianella-Borradori A, Long Z et al. A phase 1-2 clinical trial of gene therapy for recurrent glioblastoma multiforme by tumor transduction with the herpes simplex thymidine kinase gene followed by ganciclovir. GLI328 European-Canadian Study Group. Hum Gene Ther 1999; 10: 2325-2335.
14. Crystal RG, Hirschowitz E, Lieberman M, Daly J, Kazam E, Henschke C et al. Phase I study of direct administration of a replication deficient adenovirus vector containing the E. coli cytosine deaminase gene to metastatic colon carcinoma of the liver in association with the oral administration of the pro-drug 5-fluorocytosine. Hum Gene Ther 1997; 8: 985-1001.
15. Freytag SO, Khil M, Stricker H, Peabody J, Menon M, DePeralta-Venturina M et al. Phase I study of replication-competent adenovirus-mediated double suicide gene therapy for the treatment of locally recurrent prostate cancer. Cancer Res 2002; 62: 4968-4976.
16. Rainov NG. A phase III clinical evaluation of herpes simplex virus type 1 thymidine kinase and ganciclovir gene therapy as an adjuvant to surgical resection and radiation in adults with previously untreated glioblastoma multiforme. Hum Gene Ther 2000; 11: 2389-2401.
17. Haisma HJ, van Muijen M, Pinedo HM, Boven E. Comparison of two anthracycline-based prodrugs for activation by a monoclonal antibody-beta- glucuronidase conjugate in the specific treatment of cancer. Cell Biophys 1994; 24-25: 185-192.
18. Houba PH, Boven E, van der Meulen-Muileman IH, Leenders RG, Scheeren JW, Pinedo HM et al. A novel doxorubicin-glucuronide prodrug DOX-GA3 for tumour-selective chemotherapy: distribution and efficacy in experimental human ovarian cancer. Br J Cancer 2001; 84: 550-557.
19. Schmidt F, Monneret C. Prodrug Mono Therapy: synthesis and biological evaluation of an etoposide glucuroni-deprodrug. BioorgMed Chem 2003; 11: 2277-2283.
20. Leu YL, Roffler SR, Chern JW. Design and synthesis of water-soluble glucuronide derivatives of camptothecin for cancer prodrug monotherapy and antibody-directed enzyme prodrug therapy (ADEPT). J Med Chem 1999; 42: 3623-3628.
21. Angenault S, Thirot S, Schmidt F, Monneret C, Pfeiffer B, Renard P. Cancer chemotherapy: a SN-38 (7-ethyl-10-hydroxycamptothecin) glucuronide prodrug for treatment by a PMT (Prodrug MonoTherapy) strategy. Bioorg Med Chem Lett 2003; 13: 947-950.
22. de Bont DB, Leenders RG, Haisma HJ, van der Meulen-Muileman I, Scheeren HW. Synthesis and biological activity of beta-glucuronyl carbamate-based prodrugs of paclitaxel as potential candidates for ADEPT. Bioorg Med Chem 1997; 5: 405-414.
23. Bouvier E, Thirot S, Schmidt F, Monneret C. First enzymatically activated Taxotere prodrugs designed for ADEPT and PMT. Bioorg Med Chem 2004; 12: 969-977.
24. Wang SM, Chern JW, Yeh MY, Ng JC, Tung E, Roffler SR. Specific activation of glucuronide prodrugs by antibody-targeted enzyme conjugates for cancer therapy. Cancer Res 1992; 52: 4484-4491.
25. Lougerstay-Madec R, Florent JC, Monneret C, Nemati F, Poupon MF. Synthesis of self-immolative glucuronide-based prodrugs of a phenol mustard. Anticancer Drug Des 1998; 13: 995-1007.
26. Cheng TL, Chou WC, Chen BM, Chern JW, Roffler SR. Characterization of an antineoplastic glucuronide prodrug. Biochem Pharmacol 1999; 58: 325-328.
27. Cheng TL, Wei SL, Chen BM, Chern JW, Wu MF, Liu PW et al. Bystander killing of tumour cells by antibody-targeted enzymatic activation of a glucuronide prodrug. Br J Cancer 1999; 79: 1378-1385.
28. Weyel D, Sedlacek HH, Muller R, Brusselbach S. Secreted human beta-glucuronidase: a novel tool for gene-directed enzyme prodrug therapy. Gene Therapy 2000; 7: 224-231.
29. Heine D, Muller R, Brusselbach S. Cell surface display of a lysosomal enzyme for extracellular gene-directed enzyme prodrug therapy. Gene Therapy 2001; 8: 1005-1010.
30. Bosslet K, Czech J, Hoffmann D. Tumor-selective prodrug activation by fusion protein-mediated catalysis. Cancer Res 1994; 54: 2151-2159.
31. Chen BM, Chan LY, Wang SM, Wu MF, Chern JW, Roffler SR. Cure of malignant ascites and generation of protective immunity by monoclonal antibody-targeted activation of a glucuronide prodrug in rats. Int J Cancer 1997; 73: 392-402.
32. Cheng TL, Chen BM, Chern JW, Wu MF, Roffler SR. Efficient clearance of poly(ethylene glycol)-modified immunoenzyme with anti-PEG monoclonal antibody for prodrug cancer therapy. Bioconjug Chem 2000; 11: 258-266.
33. Bosslet K, Straub R, Blumrich M, Czech J, Gerken M, Sperker B et al. Elucidation of the mechanism enabling tumor selective prodrug monotherapy. Cancer Res 1998; 58: 1195-1201.
34. Prijovich ZM, Chen BM, Leu YL, Chern JW, Roffler SR. Anti-tumour activity and toxicity of the new prodrug 9-aminocamptothecin glucuronide (9ACG) in mice. Br J Cancer 2002; 86: 1634-1638.
35. Roffler SR, Wang SM, Chern JW, Yeh MY, Tung E. Anti-neoplastic glucuronide prodrug treatment of human tumor cells targeted with a monoclonal antibody-enzyme conjugate. Biochem Pharmacol 1991; 42: 2062-2065.
36. Cheng TL, Chen BM, Chan LY, Wu PY, Chern JW, Roffler SR. Poly(ethylene glycol) modification of beta-glucuronidase-antibody conjugates for solid-tumor therapy by targeted activation of glucuronide prodrugs. Cancer Immunol Immunother 1997; 44: 305-315.
37. Hsiang YH, Hertzberg R, Hecht S, Liu LF. Camptothecin induces protein-linked DNA breaks via mammalian DNA topoisomerase I. J Biol Chem 1985; 260: 14873-14878.
38. Hsiang YH, Liu LF, Wall ME, Wani MC, Nicholas AW, Manikumar G et al. DNA topoisomerase I-mediated DNA cleavage and cytotoxicity of camptothecin analogues. Cancer Res 1989; 49: 4385-4389.
39. Cheng TL, Wu PY, Wu MF, Chern JW, Roffler SR. Accelerated clearance of polyethylene glycol-modified proteins by anti-polyethylene glycol IgM. Bioconjug Chem 1999; 10: 520-528.
40. Wu CH, Balasubramanian WR, Ko YP, Hsu G, Chang SE, Prijovich ZM et al. A simple method for the production of recombinant proteins from mammalian cells. Biotechnol Appl Biochem 2004; 40: 167-172.
41. Chou WC, Liao KW, Lo YC, Jiang SY, Yeh MY, Roffler SR. Expression of chimeric monomer and dimer proteins on the plasma membrane of mammalian cells. Biotechnol Bioeng 1999; 65: 160-169.
42. Liao KW, Chen BM, Liu TB, Tzou SC, Lin YM, Lin KF et al. Stable expression of chimeric anti-CD3 receptors on mammalian cells for stimulation of antitumor immunity. Cancer Gene Ther 2003; 10: 779-790.
43. Marshall CJ, Franks LM, Carbonell AW. Markers of neoplastic transformation in epithelial cell lines derived from human carcinomas. J Natl Cancer Inst 1977; 58: 1743-1751.
44. Liao KW, Chou WC, Lo YC, Roffler SR. Design of transgenes for efficient expression of active chimeric proteins on mammalian cells. Biotechnol Bioeng 2001; 73: 313-323.
45. Tannock IF, Rotin D. Acid pH in tumors and its potential for therapeutic exploitation. Cancer Res 1989; 49: 4373-4384.
46. Su YC, Chuang KH, Wang YM, Cheng CM, Lin SR, Wang JY et al. Gene expression imaging by enzymatic catalysis of a fluorescent probe via membrane-anchored β-glucuronidase. Gene Therapy (Submitted).
47. Liao KW, Lo YC, Roffler SR. Activation of lymphocytes by anti-CD3 single-chain antibody dimers expressed on the plasma membrane of tumor cells. Gene Therapy 2000; 7: 339-347.
48. Jain S, Drendel WB, Chen ZW, Mathews FS, Sly WS, Grubb JH. Structure of human beta-glucuronidase reveals candidate lysosomal targeting and active-site motifs. Nat Struct Biol 1996; 3: 375-381.
49. Zhen L, Rusiniak ME, Swank RT. The beta-glucuronidase propeptide contains a serpin-related octamer necessary for complex formation with egasyn esterase and for retention within the endoplasmic reticulum. J Biol Chem 1995; 270: 11912-11920.
50. Murray D, Meyn RE. Cell cycle-dependent cytotoxicity of alkylating agents: determination of nitrogen mustard-induced DNA cross-links and their repair in Chinese hamster ovary cells synchronized by centrifugal elutriation. Cancer Res 1986; 46: 2324-2329.
51. Chen BM, Chen JY, Kao M, Lin JB, Yu MH, Roffler SR. Elevated topoisomerase I activity in cervical cancer as a target for chemoradiation therapy. Gynecol Oncol 2000; 79: 272-280.
52. de Graaf M, Nevalainen TJ, Scheeren HW, Pinedo HM, Haisma HJ, Boven E. A methylester of the glucuronide prodrug DOX-GA3 for improvement of tumor-selective chemotherapy. Biochem Pharmacol 2004; 68: 2273-2281.
53. Sharma SK, Bagshawe KD, Melton RG, Sherwood RF. Human immune response to monoclonal antibody-enzyme conjugates in ADEPT pilot clinical trial. Cell Biophys 1992; 21: 109-120.
54. Freytag SO, Stricker H, Pegg J, Paielli D, Pradhan DG, Peabody J et al. Phase I study of replication-competent adenovirus-mediated double-suicide gene therapy in combination with conventional-dose three-dimensional conformal radiation therapy for the treatment of newly diagnosed, intermediate- to high-risk prostate cancer. Cancer Res 2003; 63: 7497-7506.